Publications by authors named "Joel Freiman"
Serotonin produced by neuroendocrine tumors is believed to be a principal cause of the diarrhea in carcinoid syndrome. We assessed the safety and efficacy of telotristat etiprate, an oral serotonin synthesis inhibitor, in patients with diarrhea associated with carcinoid syndrome. In this prospective, randomized study, patients with evidence of carcinoid tumor and ≥4 bowel movements (BMs)/day despite stable-dose octreotide LAR depot therapy were enrolled in sequential, escalating, cohorts of four patients per cohort.
View Article and Find Full Text PDFArticle Synopsis
- LX4211 is a new medication that inhibits two glucose transporters, SGLT1 and SGLT2, which play key roles in glucose absorption and reabsorption in the body, impacting blood sugar levels and hormone release.
- The study aimed to find out how the timing of LX4211 doses in relation to meals affects its effectiveness on glucose levels and hormone release in twelve healthy participants.
- Results showed that taking LX4211 right before breakfast led to the best outcomes in controlling blood sugar and increasing beneficial hormones, with the treatment being well tolerated and no adverse effects like diarrhea reported.
Article Synopsis
- SGLT1 and SGLT2 are key transporters for glucose absorption in the intestines and kidneys, respectively, and LX4211 is a new drug that inhibits both to lower glucose levels.
- The study involves a phase 2 clinical trial to assess LX4211's safety and effectiveness in type 2 diabetes patients who aren't well-controlled on metformin alone.
- The main goal is to measure changes in glycated hemoglobin A1c over 12 weeks, with secondary goals looking at fasting glucose, body weight, blood pressure, and safety concerns like hypoglycemia and GI issues.
Article Synopsis
- Combination therapy for type 2 diabetes may improve glycemic control by using sodium-dependent glucose transporter (SGLT)-1 inhibitors alongside DPP-4 inhibitors to enhance GLP-1 levels.
- A study compared the effects of LX4211 and sitagliptin, both individually and together, on various hormones and glucose levels in mice and patients with T2DM.
- Results showed a synergistic effect in mice and increased levels of active GLP-1 and PYY in the combination therapy group, suggesting this approach could be effective for managing diabetes.
Background & Aims: Serotonin (5-hydroxytryptamine [5-HT]) has an important role in gastrointestinal function. LX1031 is an oral, locally acting, small molecule inhibitor of tryptophan hydroxylase (TPH). Local inhibition of TPH in the gastrointestinal tract might reduce mucosal production of serotonin (5-HT) and be used to treat patients with nonconstipating irritable bowel syndrome (IBS).
View Article and Find Full Text PDF